Horumarinta Geedi-socodka Horumarinta Dawooyinka
Warbixin guud
faylalka fasalka koowaad iyo kan ugu wanaagsan waxaa loogu talagalay inay wax ka qabato baahiyaha caafimaad ee aan la daboolin iyada oo loo marayo horumarinta daweynta borotiinka mono iyo bi-u-gaar ah, isku-xidhka daawada antibody-ga iyo wakiilada kicinta makrophage ee bukaannada adduunka oo dhan.
Taariikhda
Daah-furkii ugu dambeeyay ee tignoolajiyada monoclonal antibody (mAb) ee Kohler iyo Milstein ee 1975 waxay siisay suurtogalnimada abuurista unugyada difaaca jirka sida fasalka daweynta (Kohler & Milstein, 1975).Unugyada difaaca jirka ee monoclonal (mAbs) waa mid ka mid ah xarumaha daawada aadka loo isticmaalo ee cudurada faafa ama daaweynta kansarka sababtoo ah waxay si xushmad leh u bartilmaameedsadaan cudurada faafa, unugyada faafa, unugyada kansarka, iyo xitaa unugyada difaaca.Sidan oo kale, waxay dhexdhexaadiyaan baabi'inta molecules bartilmaameedka ah iyo unugyada leh waxyeellooyin ka yar hababka kale ee daaweynta.Gaar ahaan, mAbs-da daaweynta kansarka waxay aqoonsan karaan borotiinnada dusha-unugyada ee unugyada bartilmaameedka ka dibna waxay dilaan unugyada la beegsaday habab badan.
Bani'aadamnimadu waxay si weyn u yaraynaysaa difaaca jirka ee ka hortagga jirka ee bini'aadamka, taasoo ka dhigaysa maamul daba-dheeraad ah.Horumarka noocan oo kale ah ee tignoolajiyada kahortaga jirka ayaa sababay qarax horumarinta mAbs-daweynta tobankii sano ee la soo dhaafay.Taxanayaal ka-hortagga unugyada, oo ay ku jiraan borotiinnada Fc-fusions, isku-xidhayaasha-daawoyinka-daawoyinka (ADCs), immunocytokines (fiyuusyada antibody-cytokine), iyo fusions antibody-enzyme, ayaa sidoo kale la soo saaray oo laga ganacsan jiray sidii daaweyn cusub.
Saamaynta daroogada
Bukaannada, dawooyinka cusub ee la bar tilmaameedsado waxay ka dhigan yihiin waxyeellooyin yar, isbitaal dhigis yar, tayada nolosha oo hagaagtay, korodhka wax soo saarka, iyo muhiimada, nolosha dheer.Laakiin horumarinta maandooriyaha waa hab dheer oo adag.
Tixraac
Kohler G, Milstein C. Dhaqamada joogtada ah ee unugyada isku dhafan ee qarsoodiya antibody-ka gaarka ah.Dabeecadda.1975;256:495–497.doi: 10.1038/256495a0
Ecker DM, Jones SD, Levine HL.Therapeutic monoclonal antibody suuqa.MAbs2015;7:9–14.doi: 10.4161/19420862.2015.989042.
Peters C, Brown S. Antibody-daawoyinka isku xira sida kiimiko-daaweedka cusub ee ka hortagga kansarka.Biosci Rep. 2015;35(4):e00225.La daabacay 2015 Jul 14. Waxaa laga heli karaa https://pubmed.ncbi.nlm.nih.gov/26182432/.La galay Luulyo 2020.
Reichert, JM, iyo Valge-Archer, VE (2007).Isbeddellada horumarinta ee daaweynta kansarka ka hortagga unugyada monoclonal.Nat Rev Drug Discov 6, 349-356.
Lazar, GA, Dang, W., Karki, S., Vafa, O., Peng, JS, Hyun, L., Chan, C., Chung, HS, Eivazi, A., Yoder, SC, iyo al.(2006).Kala duwanaanshiyaha antibody Fc ee la farsameeyay oo leh shaqa wax qabad oo la xoojiyey.PNAS 103, 4005-4010.
Injineer farsamo yaqaan ah oo u heellan inuu ku hago
Marka loo eego baahiyahaaga dhabta ah, dooro qaabka guud ee ugu macquulsan iyo hababka qorshaynta